When 10-month-old Noa Greenwood was diagnosed with a rare genetic disease, her parents, Lee and Lori were confronted with an idea of a future they'd never prepared for; the likelihood that their daughter would not progress beyond the abilities of a six-month-old and may not live past her 10th birthday.
Noa is one of more than 30 million Americans living with a rare disease. Fewer than 5% of these diseases have an FDA-approved treatment, leaving the people behind these numbers waiting for a treatment.
Many rare diseases are comprised of relatively small patient populations, often considered too small a market for traditional pharma to fund; even when medical researchers had found potential therapies.
BridgeBio is built on a new model, finding therapies for rare genetic diseases using clearer biology, faster learning, and smarter financing. Noa's story is what that looks like in a single life and a reason for hope for the millions of families still waiting for answers.